Alzheimer Disease News

• Alert FDA Approves Second Anti-Amyloid for Alzheimer's Disease The US Food and Drug Administration has approved lecanemab for patients with Alzheimer's disease, even though trial results showed modest cognitive benefits and cases of amyloid-related imaging abnormalities.
  FDA Approvals, January 06, 2023
• Lecanemab Linked to Death in AD Patient With Stroke Given tPA A case report links the investigational Alzheimer's drug to numerous severe intracerebral hemorrhages during thrombolysis treatment.
  Medscape Medical News, January 04, 2023
• Congressional Report: FDA Broke Own Protocols in Approving Biogen Alzheimer's Drug The FDA failed to adhere to its own guidance and internal practices during the approval process for Biogen's Alzheimer's drug Aduhelm, which was 'rife with irregularities,' a congressional report showed on Thursday.
  Reuters Health Information, December 29, 2022
• Strong Link Between Muscle Strength, Mobility, and Brain Health Higher handgrip strength and better mobility correlate with larger brain volumes in cognitively impaired adults with biomarker evidence of dementia.
  Medscape Medical News, December 29, 2022
• Green, Blue Space Linked to Fewer Parkinson's Hospitalizations Living in areas with green space (such as with trees and gardens) and with "blue space" (such as with rivers) may lower hospitalizations for patients with neurodegenerative disorders, new research suggests.
  Medscape Medical News, December 28, 2022
• Eisai, Biogen's New Alzheimer's Drug Should Be Priced Below Aduhelm: Report An influential drug pricing research group said Eisai and Biogen's new Alzheimer's disease treatment lecanemab should be priced lower than the drug Aduhelm that was developed by the companies.
  Reuters Health Information, December 23, 2022
• Alzheimer's Association to CMS: Ditch Restraints on Amyloid Drugs With novel drug lecanemab on the horizon, the Alzheimer Association is asking the CMS to reverse its policy and provide full and unrestricted coverage to FDA-approved anti-amyloid agents.
  Medscape Medical News, December 21, 2022
• Psychological Distress May Up Dementia Risk Symptoms of psychological distress is significantly linked to dementia development ― and can raise the risk for dementia later in life by as much as 24%, new research shows.
  Medscape Medical News, December 20, 2022
• Is There Hope in the Fight Against Aging? A clinician summarizes recent advances in our understanding of the mechanisms underlying biological aging.
  Medscape Medical News, December 19, 2022
• Genetic Predisposition to ADHD Linked to Alzheimer's Risk A new study is the first to show a link between genetic risk for attention- deficit/hyperactivity disorder and increased odds of developing late-onset Alzheimer's disease, researchers say.
  Medscape Medical News, December 16, 2022
• AES 2022 Seizures in Dementia Hasten Decline and Death Patients with dementia and active seizures experience faster cognitive and functional decline, and have a greater risk of dying younger, than those with dementia but without seizures, new research shows.
  MDedge News, December 14, 2022
• Alert FDA Clears Two Biomarker Assays for Early Alzheimer's Detection The Elecsys beta-amyloid (1-42) CSF II and Elecsys phospho-tau (181P) CSF assays are for use in adults aged 55 and older who are being evaluated for cognitive difficulties.
  Medscape Medical News, December 09, 2022
• CTAD 2022 Exercise to Prevent Cognitive Decline in MCI: New Data Exercise does not prevent cognitive decline in patients with mild cognitive impairment but may preserve cognition, new research shows.
  Medscape Medical News, December 09, 2022
• Voice Could Be a Major New Biomarker The NIH is investing millions to investigate voice analysis as a tool for diagnosing a wide range of diseases, including Alzheimer's, depression, and autism.
  WebMD Health News, December 08, 2022
• Off-Label Use of Dementia Meds Tied to Lower Mortality in DLB Off-label use of acetylcholinesterase inhibitors and memantine is associated with better survival following hospitalization for patients with dementia with Lewy bodies (DLB).
  Medscape Medical News, December 06, 2022
• Ultraprocessed Foods Tied to Faster Rate of Cognitive Decline Results of a large observational study suggest limiting ultraprocessed foods, which are high in sugar, salt, and fat, to protect brain health.
  Medscape Medical News, December 06, 2022
• Lecanemab a Game-Changer for Alzheimer's? Not So Fast A Lancet editorial calls for 'tempering hype and hope' over lecanemab for Alzheimer's disease, which provided modest benefit with safety concerns in the CLARITY AD trial.
  Medscape Medical News, December 05, 2022
• CTAD 2022 Antipsychotic Shows Benefit for Alzheimer's Agitation Researchers reported that a phase 3 study showed statistically significant improvement in patients with agitation related to Alzheimer's who took the atypical antipsychotic brexpiprazole.
  Medscape Medical News, December 05, 2022
• 'Convincing Evidence' Hearing Aids Reduce Dementia Risk A large meta-analysis provides the best evidence to date that hearing restorative devices reduce the risk for cognitive decline and dementia and even improve short-term cognitive function
  Medscape Medical News, December 05, 2022
• CTAD 2022 Personalized Approach to Alzheimer's Risk Factors Boosts Cognition A personalized intervention that focused on known Alzheimer's risk factors showed "modest" improvement at 2 years that was greater than a control intervention, new results from the SMAART study show.
  Medscape Medical News, December 05, 2022